Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Plasma Cell Myeloma Clinical Trial

Official title:

Phase II Randomized Trial of Continuation of Post-Transplant Maintenance With Single-Agent Lenalidomide vs. Consolidation/Maintenance With Ixazomib-Lenalidomide-Dexamethasone in Patients With Residual Myeloma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02389517
• Other study ID #: IRB14-0899
• Secondary ID: NCI-2015-00138X1
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 2, 2015
• Est. completion date: March 2024

Study information

• Verified date: April 2023
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells and may also prevent the growth of new blood vessels that are needed for cancer growth. Ixazomib citrate may stop the growth of cancer cells by interfering with proteins necessary for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether lenalidomide is more effective with or without ixazomib citrate and dexamethasone in treating residual multiple myeloma.

Description:

PRIMARY OBJECTIVES:

I. To determine the rate of minimal residual disease (MRD)-negative disease by multiparameter-flow cytometry at 12 months after randomization.

SECONDARY OBJECTIVES:

I. Evidence of response as demonstrated by the improvement of the depth of response by at least one category according to International Myeloma Working Group (IMWG) response criteria.

II. Progression free survival (PFS). III. Overall survival (OS). IV. Duration of MRD-negative disease. V. Safety and tolerability of experimental arm (ixazomib citrate, lenalidomide, and low dose dexamethasone [IRd]) vs. control arm (lenalidomide [Rd]).

TERTIARY OBJECTIVES:

I. Determination of markers of response based on pre-treatment characteristics using methods described in correlative research.

II. Evaluation of MRD by gene sequencing method using the Sequenta platform (LymphoSIGHT®) in parallel with multi-parameter flow cytometry (MFC).

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive ixazomib citrate orally (PO) on days 1, 8, and 15, lenalidomide PO once daily (QD) on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).

ARM II: Patients receive lenalidomide PO as in Arm I.

In both arms, treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.

After the completion of treatment, patients are followed up at 30 days and then every 3 months for 2 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 42
• Est. completion date: March 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who completed induction treatment followed by autologous stem cell transplant as initial therapy for symptomatic myeloma as per IMWG criteria and initiated Revlimid (lenalidomide) maintenance

• Patients must have initiated lenalidomide maintenance at approximately 3 months post autologous stem transplant (preferably 70-90 but not more than 120 days)

• Patients must be receiving lenalidomide 10 mg or 15 mg and be able to tolerate dose escalation to 25 mg daily

• Patients must have received lenalidomide maintenance for 3 months (+1 month window for a maximum of 4 months lenalidomide prior to enrollment)

• No evidence of progressive disease on lenalidomide

• Any measurable residual disease at the time of screening for the study documented in at least one of the following ways:

• Serum protein electrophoresis (SPEP)/immunofixation studies (IFIX) positive disease

• Freelite only positive disease

• SPEP/IFIX - negative and Freelite- negative but MRD-positive disease is allowed

• Evidence of MRD at the time of screening for this study by multi-color flow cytometry (bone marrow procedure at screening required)

• Bone marrow specimen will be required at study entry; available deoxyribonucleic acid (DNA) sample will be used for calibration step for MRD evaluation by gene sequencing

• Life expectancy of more than 3 months

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

• Bilirubin =<1.5 x upper limit of normal (ULN)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN

• Absolute neutrophil count (ANC) >= 1.0 x 10^9/L

• Hemoglobin >= 8 g/dL

• Platelet count >= 75 x 10^9/L

• Calculated creatinine clearance (by Cockroft-Gault) >= 50 ml/min or serum creatinine below 2 g/dL

• Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care

• Female patients who:

• Are postmenopausal for at least 1 year before the screening visit, OR

• Are surgically sterile, OR

• If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR

• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)

• Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:

• Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR

• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)

Exclusion Criteria:

• Evidence of progressive disease on lenalidomide maintenance as per IMWG criteria

• Patients who have already started or received multi-drug consolidation regimen post-transplant expect for lenalidomide maintenance

• Diarrhea > grade 1 in the absence of anti-diarrheals

• Central nervous system involvement

• Female patients who are lactating or have a positive serum pregnancy test during the screening period

• History of allergy to mannitol

• Major surgery within 14 days before enrollment

• Radiotherapy within 14 days before randomization; if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib

• Evidence of current uncontrolled cardiovascular conditions, including uncontrolled cardiac conditions such as hypertension, or cardiac arrhythmias, or New York Heart Association stage III and IV congestive heart failure, or unstable angina or myocardial infarction within the past 6 months

• Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead electrocardiogram (ECG) during screening

• Uncontrolled diabetes

• Acute infection requiring systemic anti-infectives, antivirals, or antifungals within two weeks prior to first dose

• Systemic treatment, within 14 days before the first dose of ixazomib, with strong inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 2 (CYP1A2) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P450 family 3, subfamily A CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort

• Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive

• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol

• Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

• Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

• Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

• Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period

• Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Plasma Cell Myeloma
• Residual Disease

Intervention

Drug:
• Ixazomib Citrate
Given PO
• Lenalidomide
Given PO
• Dexamethasone
Given PO

Locations

Country	Name	City	State
United States	University of Chicago	Chicago	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
University of Chicago	Multiple Myeloma Research Foundation, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Markers of response	Correlative biomarkers will be assessed for association with response in the experimental arm using nonparametric tests given the relatively small number of responders anticipated (20%). A Wilcoxon rank-sum test will be used to compare baseline (pre-treatment) biomarker levels in the responders vs. non-responders.	Baseline
Primary	Rate of MRD between the two arms, as measured by flow cytometry and sequencing	The comparison will be made using a one sided test at the 10% significance level. This comparison will be performed using a Cochran Mantel-Haenszel (CMH) test stratified by very good partial response (VGPR) status and risk factors vs. no risk factors.	At 12 months
Secondary	Overall response rate defined as an improvement from very good partial response (VGPR) to near complete response (nCR) or better than nCR including conversion from complete response (CR) to MRD negative disease according to IMWG criteria	The rate of overall response will be reported along with its exact 95% binomial confidence interval.	At 6 months
Secondary	Overall response defined as an improvement from VGPR to nCR or better than nCR including conversion from CR to MRD negative disease according to IMWG criteria	The rate of overall response will be reported along with its exact 95% binomial confidence interval.	At 12 months
Secondary	Duration of response (MRD-negative disease)	Duration of response will be assessed conditionally upon achieving at least a partial response.	From the date of the clinical examination, which confirmed the response, until the date of disease progression, or censoring at the date of last clinical follow-up, assessed up to 2 years
Secondary	Time to progression	Time to event will be estimated using the product-limit method of Kaplan and Meier.	Up to 2 years
Secondary	Estimated PFS	Time to event will be estimated using the product-limit method of Kaplan and Meier. MRD status will be correlated with PFS.	From the date of randomization until the date of documented disease progression or death, assessed up to 2 years
Secondary	Estimated OS	Time to event will be estimated using the product-limit method of Kaplan and Meier.	Up to 2 years
Secondary	Incidence, intensity, and type of adverse events as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0	Safety variables will be tabulated and presented for all patients in the study. Exposure to study drug and reasons for discontinuation of study treatment will be tabulated. Group comparisons will be performed using chi-square or Fisher's exact test.	Up to 30 days post-treatment